Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Axim Biotechnologies (OP: AXIM )

0.6000 USD -0.0050 (-0.83%)
Streaming Delayed Price Updated: 1:23 PM EDT, Sep 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Axim Biotechnologies

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board
An Internationally Recognized Authority in Dry Eye Disease, Dr. Tauber has Participated in over 140 Research Studies as Principal Investigator 
From GlobeNewswire News Releases
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech 
From GlobeNewswire News Releases
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care
From GlobeNewswire News Releases
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
From GlobeNewswire News Releases
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells
From GlobeNewswire News Releases
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the E
From GlobeNewswire News Releases
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants
From GlobeNewswire News Releases
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care L
From GlobeNewswire News Releases
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
From GlobeNewswire News Releases
AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients
From GlobeNewswire News Releases
AXIM® Biotechnologies Releases Preprint Manuscript Describing the Development of Company’s Rapid Point-of-Care Test That Measures COVID-19 Neutralizing Antibodies
From GlobeNewswire News Releases
AXIM® Biotechnologies Completes Successful Covid-19 Live Virus Test and Files Amended EUA for Portable 10 Minute Rapid Diagnostic Test for Neutralizing Antibodies
From GlobeNewswire News Releases
AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14
From GlobeNewswire News Releases
AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application
From GlobeNewswire News Releases
AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity
From GlobeNewswire News Releases
AXIM® Biotechnologies Issues Update Letter to Shareholders
From GlobeNewswire News Releases
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
From GlobeNewswire News Releases
Medical Marijuana, Inc. Investment Company AXIM Biotechnologies Files Patent for Worlds First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)
From NewMediaWire
AXIM® Biotechnologies Files Patent for Virus Binding Recombinant Protein for SARS-CoV-2 (COVID-19) and Begins Manufacturing
From GlobeNewswire News Releases
AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 COVID-19
From GlobeNewswire News Releases
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
From GlobeNewswire News Releases
AXIM® Biotechnologies Files Emergency Use Authorization With the FDA for First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies
From GlobeNewswire News Releases
Cannabis Stock Gainers And Losers From September 1, 2020
Gainers: Body & Mind Inc (OTC: BMMJ) shares closed up 17.73% at $0.29 Auxly Cannabis Group Inc(TSE: XLY) shares closed ... 
Tags Cannabis stocks BTTR
From Benzinga
AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test
From GlobeNewswire News Releases
Sapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute
From GlobeNewswire News Releases
Cannabis Stock Gainers And Losers From August 5, 2020
Gainers: Axim Biotechnologies(OTC: AXIM) shares closed up 17.23% at $0.83 AusCann Group Holdings(OTC: ACNNF) shares ... 
Tags IMLFF BMMJ FLOOF
From Benzinga
AXIM® Biotechnologies Applies for FDA Emergency Use Approval (EUA) for High Throughput, Patent-Pending Neutralizing Antibody Diagnostic Test for COVID-19
From GlobeNewswire News Releases
AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests
From GlobeNewswire News Releases
Cannabis Stock Gainers And Losers From July 22, 2020
Gainers: NexTech AR Solns(OTC: NEXCF) shares closed up 75.56% at $5.53 Driven Deliveries (OTC: DRVD) shares closed up 14% at ... 
Tags ELLXF Benzinga NXGWF
From Benzinga
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.